Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
, 20 (1), 1-19

Japanese Gastric Cancer Treatment Guidelines 2014 (Ver. 4)

Practice Guideline

Japanese Gastric Cancer Treatment Guidelines 2014 (Ver. 4)

Japanese Gastric Cancer Association. Gastric Cancer.

Conflict of interest statement

Dr. Kodera reports grants and personal fees from Taiho Pharmaceutical, Chugai Phamaceutical, Sanofi, Merck Serono, Yakult Honsha, Daiichi Sankyo, Otsuka Pharmaceutical Factory, Takeda Pharmaceutical, Johnson & Johnson, Asahi Kasei Pharma, Eli Lilly Japan, Pfizer Japan, AJINOMOTO Pharmaceuticals, ONO Pharmaceutical and Kaken Pharmaceutical and grants from Covidien Japan, Shionogi, Bristol Myers Squib, Japan Blood Products Organization, Torii Pharmaceutical, Mitsubishi Tanabe Pharma, bbVie GK, Otsuka Pharmaceutical, Yoshindo, Eizai, Abbott Japan, CSL Behring, Teijin Pharma, Tsumura, Nippon Kayaku, Miyarisan Pharmaceutical, Novartis Pharmaceuticals Japan, KCI, Toyama Chemical, Maruho, Hogy Medical and MSD, outside the submitted work. Dr. Sano reports personal fees from Chugai Phamaceutical, Covidien Japan, Eli Lilly Japan, Johnson & Johnson, Olympus, Otsuka Pharmaceutical Factory, Taiho Pharmaceutical and Yakult Honsha.

Figures

Fig. 1
Fig. 1
Algorithm of standard treatments
Fig. 2
Fig. 2
The extent of lymphadenectomy after total gastrectomy. The numbers correspond to the lymph node station as defined in the Japanese Classification of Gastric Carcinoma (1). Complete dissection of the nodes in blue denotes D1 dissection, the nodes in orange D1+ and the nodes in red D2
Fig. 3
Fig. 3
The extent of lymphadenectomy after distal gastrectomy. The numbers correspond to the lymph node station as defined in the Japanese Classification of Gastric Carcinoma (1). Complete dissection of the nodes in blue denotes D1 dissection, the nodes in orange D1+ and the nodes in red D2
Fig. 4
Fig. 4
The extent of lymphadenectomy after pylorus-preserving gastrectomy. The numbers correspond to the lymph node station as defined in the Japanese Classification of Gastric Carcinoma (1). Complete dissection of the nodes in blue denotes D1 dissection and the nodes in orange D1+
Fig. 5
Fig. 5
The extent of lymphadenectomy after proximal gastrectomy. The numbers correspond to the lymph node station as defined in the Japanese Classification of Gastric Carcinoma (1). Complete dissection of the nodes in blue denotes D1 dissection and the nodes in orange D1+
Fig. 6
Fig. 6
Algorithm showing the tentative standard in the extent of lymphadenectomy for junctional cancer based on the tumor location, histology and T-categories
Fig. 7
Fig. 7
Algorithm showing treatment of early gastric cancer according to the histopathologic findings of the specimens resected by ESD

Similar articles

See all similar articles

Cited by 451 PubMed Central articles

See all "Cited by" articles

References

    1. Japanese Gastric Cancer Association Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–112. doi: 10.1007/s10120-011-0041-5. - DOI - PubMed
    1. Kaminishi M, Yamaguchi H, Shimizu N, et al. Stomach-partitioning gastrojejunostomy for unresectable gastric carcinoma. Arch Surg. 1997;132:184–187. doi: 10.1001/archsurg.1997.01430260082018. - DOI - PubMed
    1. Fujitani K, Yang HK, Mizusawa J, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17:309–318. doi: 10.1016/S1470-2045(15)00553-7. - DOI - PubMed
    1. Sano T, Sasako M, Mizusawa J, et al. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma. Ann Surg. 2016 (Epub ahead of print). - PubMed
    1. Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359:453–462. doi: 10.1056/NEJMoa0707035. - DOI - PubMed

Publication types

Feedback